These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 28956258)

  • 1. Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.
    Chait A; Goldberg I
    Curr Diab Rep; 2017 Sep; 17(11):112. PubMed ID: 28956258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes.
    Karalis DG
    Clin Cardiol; 2008 Jun; 31(6):241-8. PubMed ID: 17847038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease.
    Vavlukis M; Kedev S
    Curr Pharm Des; 2018; 24(4):427-441. PubMed ID: 29283060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.
    Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF
    Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.
    Bosomworth NJ
    Can Fam Physician; 2013 Nov; 59(11):1169-80. PubMed ID: 24235189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment approaches for diabetes and dyslipidemia.
    Wu M; Lyons TJ
    Horm Res Paediatr; 2011; 76 Suppl 1(Suppl 1):76-80. PubMed ID: 21778754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
    Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel strategies for managing dyslipidemia: treatment beyond statins.
    Ling H; Burns TL; Hilleman DE
    Postgrad Med; 2012 Nov; 124(6):43-54. PubMed ID: 23322138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
    Anabtawi A; Moriarty PM; Miles JM
    Curr Cardiol Rep; 2017 Jul; 19(7):62. PubMed ID: 28528456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug therapy of diabetic dyslipidemia: do the statins suffice?
    Mooradian AD
    Am J Ther; 2015; 22(1):87-8. PubMed ID: 23728161
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of dyslipidemia and cardiovascular outcomes: the journey so far--is this the end for statins?
    Zoungas S; Curtis AJ; McNeil JJ; Tonkin AM
    Clin Pharmacol Ther; 2014 Aug; 96(2):192-205. PubMed ID: 24727468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CONTROVERSIAL ISSUES IN THE TREATMENT OF DYSLIPIDEMIAS IN PATIENTS WITH DIABETES MELLITUS.
    Parhofer KG
    Rev Invest Clin; 2018; 70(5):237-243. PubMed ID: 30307445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of diabetic dyslipidemia: need for reappraisal of the goals.
    Khera A; McGuire DK
    Am J Cardiovasc Drugs; 2005; 5(2):83-91. PubMed ID: 15725039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.